BAYER AG

Maven Clinic raises $125M in Series F, becoming the highest valued digital health company in women’s and family health. Other highlights include Levy securing $4.5M seed funding for fertility diagnosis, Rezilient Health raising $10M Series A for tech-enabled family healthcare, and Marlow securing $1.9M for a novel lubricated tampon product. Panasonic Well launches a Family Wellness Innovation Challenge with $1 million in equity-free prizes.

The global High Potency APIs (HPAPIs) market is projected to reach $46.9 Billion by 2030, driven by the expansion of oncology, hormonal, and endocrine therapies. Key factors include the rise in cancer diagnoses, targeted therapies, advancements in drug delivery, and the expansion of CMOs specializing in HPAPI production.

Recent acquisitions of cancer drug developers RayzeBio and Fusion Pharmaceuticals highlight radiotherapy's resurgence. Oncology sees advancements in genetics, immunology, AI, and personalized treatments. Funding remains robust, with potential for highest corporate rounds since 2021. Combination therapies and AI are crucial, with cancer vaccines and precision treatments offering hope. Despite challenges, progress in treating specific cancers has improved patient outcomes.

The precision medicine market is projected to grow from $75.2 billion in 2023 to $168.3 billion by 2032, driven by advancements in genomics, rising chronic disease prevalence, and personalized healthcare. Key trends include AI integration and companion diagnostics. Challenges like high costs and complex regulations offer opportunities for innovation. North America leads in market share, with Europe and Asia-Pacific also showing significant growth.

FDA accepts NDA for elinzanetant, a dual NK-1,3 receptor antagonist, for treating moderate to severe VMS in menopause. Positive phase 3 OASIS trials show elinzanetant reduces VMS frequency and severity, improves sleep and quality of life, with favorable safety data. Elinzanetant could offer a non-hormonal treatment option if approved.

Milan's IP court shake-up impacts proceedings; Italian Supreme Court's Bolar exemption interpretation affects pharma litigation. Trevisan & Cuonzo and Bird & Bird lead in patent disputes, with firms like Hogan Lovells and Simmons & Simmons also prominent. Italian IP boutiques maintain strong presence, often combining academic work with litigation.

DelveInsight's Menopause Market Insights, Epidemiology, and Market Forecast-2034 report analyzes market trends, epidemiology, and emerging therapies in the US, EU4, UK, and Japan. Key companies include GlaxoSmithKline, Pfizer, Bayer, and others. The market size was ~USD 10,968 million in 2022, with hormonal therapy dominating but expected to decline as non-hormonal therapies gain prevalence. Notable therapies include VEOZAH, a non-hormonal treatment approved by the FDA in 2023.

Syneos Health appoints Costa Panagos as CEO, succeeding Colin Shannon who becomes Executive Chairman. Panagos, with 25+ years in CRO leadership, aims to build on Syneos Health's momentum and deliver differentiated offerings from early development to commercialization.

FDA accepts Bayer's NDA for elinzanetant, a dual NK-1 and 3 receptor antagonist for treating moderate to severe VMS in menopause, based on positive OASIS Phase III study results.

The agricultural biotechnology market is projected to grow from $55.24 billion in 2023 to $89.52 billion by 2028, driven by increased food demand, technological innovations, and sustainable practices. Key players like BASF SE and Bayer AG focus on integrated solutions to enhance productivity and sustainability.